An OHSS-Free Clinic by segmentation of IVF treatment

Human Reproduction
26, 2593-2597
DOI: 10.1093/humrep/der251

Citation Report

#	Article	IF	Citations
1	Oocyte cryopreservation for age-related fertility loss. Human Reproduction, 2012, 27, 1231-1237.	0.4	199
2	Significantly lower ectopic pregnancy rates after frozen embryo transfer: implications toward segmentation of inÂvitro fertilization treatment. Fertility and Sterility, 2012, 98, 1419-1420.	0.5	14
3	Comparative incidence of ovarian hyperstimulation syndrome following ovarian stimulation with corifollitropin alfa or recombinant FSH. Reproductive BioMedicine Online, 2012, 24, 410-419.	1.1	24
4	Development of a nomogram based on markers of ovarian reserve for the individualisation of the follicleâ€stimulating hormone starting dose in in vitro fertilisation cycles. BJOG: an International Journal of Obstetrics and Gynaecology, 2012, 119, 1171-1179.	1.1	117
5	Agonist trigger: what is the best approach? Agonist trigger with vitrification of oocytes or embryos. Fertility and Sterility, 2012, 97, 527-528.	0.5	42
6	Agonist and antagonist coast. Fertility and Sterility, 2012, 97, 523-526.	0.5	15
7	Efficiency of slush nitrogen vitrification of human oocytes vitrified with or without cumulus cells in relation to survival rate and meiotic spindle competence. Fertility and Sterility, 2012, 97, 1220-1225.	0.5	23
8	Elimination of ovarian hyperstimulation syndrome. Fertility and Sterility, 2012, 97, e29.	0.5	1
9	Obstetric and perinatal outcomes in singleton pregnancies resulting from the transfer of frozen thawed versus fresh embryos generated through inÂvitro fertilization treatment: a systematic review and meta-analysis. Fertility and Sterility, 2012, 98, 368-377.e9.	0.5	437
10	Oocyte vitrification does not increase the risk of embryonic aneuploidy or diminish the implantation potential ofÂblastocysts created after intracytoplasmic sperm injection: a novel, paired randomized controlled trial using DNA fingerprinting. Fertility and Sterility, 2012, 98, 644-649.	0.5	130
11	GnRH agonist versus GnRH antagonist in in vitro fertilization and embryo transfer (IVF/ET). Reproductive Biology and Endocrinology, 2012, 10, 26.	1.4	90
12	Balancing selected medication costs with total number of daily injections: a preference analysis of GnRH-agonist and antagonist protocols by IVF patients. Reproductive Biology and Endocrinology, 2012, 10, 67.	1.4	16
13	Outpatient management of severe early OHSS by administration of GnRH antagonist in the luteal phase: an observational cohort study. Reproductive Biology and Endocrinology, 2012, 10, 69.	1.4	40
14	Ovulation Stimulation and Cycle Management in IVF. , 2012, , 31-53.		0
15	Implications of oocyte cryostorage for the practice of oocyte donation. Human Reproduction, 2012, 27, 2886-2893.	0.4	27
19	A â€œfreeze-allâ€•embryo strategy afterÂinÂvitro maturation: a novel approach in women with polycystic ovary syndrome?. Fertility and Sterility, 2013, 100, 1002-1007.e1.	0.5	51
20	A prediction model to select PCOS patients suitable for IVM treatment based on anti-Mullerian hormone and antral follicle count. Human Reproduction, 2013, 28, 1261-1266.	0.4	43
21	Predictors of ovarian response in women treated with corifollitropin alfa for inÂvitro fertilization/intracytoplasmic sperm injection. Fertility and Sterility, 2013, 100, 430-437.	0.5	52

#	Article	IF	Citations
22	Fertility preservation in women. Nature Reviews Endocrinology, 2013, 9, 735-749.	4.3	262
23	Impact of GnRH agonist triggering and intensive luteal steroid support on live-birth rates and ovarian hyperstimulation syndrome: a retrospective cohort study. Journal of Ovarian Research, 2013, 6, 93.	1.3	38
25	GnRH agonist triggering: recent developments. Reproductive BioMedicine Online, 2013, 26, 226-230.	1.1	86
26	Venous thrombosis during assisted reproduction: Novel risk reduction strategies. Thrombosis Research, 2013, 131, S1-S3.	0.8	27
27	Does the time interval between antimÃ¼llerian hormone serum sampling and initiation of ovarianÂstimulation affect its predictive ability in inÂvitro fertilizationâ€“intracytoplasmic spermÂinjection cycles with a gonadotropin-releasing hormone antagonist? A retrospective single-center study. Fertility and Sterility, 2013, 100, 438-444.	0.5	24
28	Low tolerance for complications. Fertility and Sterility, 2013, 100, 299-301.	0.5	7
29	Biomarkers of ovarian response: current and future applications. Fertility and Sterility, 2013, 99, 963-969.	0.5	183
30	The health risks of ART. EMBO Reports, 2013, 14, 129-135.	2.0	26
31	A feasible strategy of preimplantation genetic diagnosis for carriers with chromosomal translocation: Using blastocyst biopsy and array comparative genomic hybridization. Journal of the Formosan Medical Association, 2013, 112, 537-544.	0.8	21
32	Combination of cabergoline and embryo cryopreservation after GnRH agonist triggering prevents OHSS in patients with extremely high estradiol levelsâ€”a retrospective study. Journal of Assisted Reproduction and Genetics, 2013, 30, 753-759.	1.2	5
33	GnRH Analogues in the Prevention of Ovarian Hyperstimulation Syndrome. International Journal of Endocrinology and Metabolism, 2013, 11, 107-16.	0.3	11
34	GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients. Human Reproduction, 2013, 28, 2511-2521.	0.4	197
35	Ovarian hyperstimulation syndrome- an optimal solution for an unresolved enigma. Journal of Ovarian Research, 2013, 6, 77.	1.3	40
36	The optimum number of oocytes in IVF treatment: an analysis of 2455 cycles in China. Human Reproduction, 2013, 28, 2728-2734.	0.4	154
37	Clinical relevance for the fact that GnRH antagonists do not down-regulate the GnRH receptor. Human Reproduction, 2013, 28, 1144-1144.	0.4	2
38	Elective single-embryo transfer in older women. Human Reproduction, 2013, 28, 1144-1145.	0.4	2
39	Turn, turn, turn. Human Reproduction, 2013, 28, 2313-2314.	0.4	1
40	Pregnancy and neonatal outcomes following luteal GnRH antagonist administration in patients with severe early OHSS. Human Reproduction, 2013, 28, 1929-1942.	0.4	34

#	Article	IF	Citations
41	Cloned human ES cells: a great leap forward, and still needed?. Molecular Human Reproduction, 2013, 19, 629-633.	1.3	1
42	Elective frozen replacement cycles for all: ready for prime time?. Human Reproduction, 2013, 28, 6-9.	0.4	91
43	Biomarkers of ovarian reserve. Biomarkers in Medicine, 2013, 7, 147-158.	0.6	21
44	Safety of ovarian stimulation. , 0, , 371-383.		0
45	Spontaneous ovarian hyperstimulation syndrome following a thawed embryo transfer cycle. Clinical and Experimental Reproductive Medicine, 2014, 41, 140.	0.5	6
46	Gn<scp>RH</scp> agonist trigger and a freezeâ€all strategy to prevent ovarian hyperstimulation syndrome: A retrospective study of <scp>OHSS</scp> risk and pregnancy rates. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2014, 54, 581-585.	0.4	17
47	Pharmaceutical Options for Triggering of Final Oocyte Maturation in ART. BioMed Research International, 2014, 2014, 1-7.	0.9	40
48	Best Protocol for Controlled Ovarian Hyperstimulation in Assisted Reproductive Technologies: Fact or Opinion?. Seminars in Reproductive Medicine, 2014, 32, 262-271.	0.5	21
49	The rate of high ovarian response in women identified at risk by a high serum AMH level is influenced by the type of gonadotropin. Gynecological Endocrinology, 2014, 30, 444-450.	0.7	20
50	The effect of ovarian puncture on the endocrine profile of PCOS patients who undergo IVM. Reproductive Biology and Endocrinology, 2014, 12, 18.	1.4	10
51	Effect of preovulatory progesterone elevation and duration of progesterone elevation on the pregnancy rate of frozenâ€“thawed embryo transfer in natural cycles. Fertility and Sterility, 2014, 101, 1288-1293.	0.5	36
52	Cabergoline for the prevention of ovarian hyperstimulation syndrome: systematic review and meta-analysis of randomized controlled trials. Fertility and Sterility, 2014, 101, 664-675.e7.	0.5	81
53	Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice. Human Reproduction Update, 2014, 20, 124-140.	5.2	417
54	Gonadotrophin-releasing hormone agonist trigger and freeze-all strategy does not prevent severe ovarian hyperstimulation syndrome: a report of three cases. Reproductive BioMedicine Online, 2014, 29, 541-544.	1.1	81
55	Cryopreserved embryo transfer in an artificial cycle: is GnRH agonist down-regulation necessary?. Reproductive BioMedicine Online, 2014, 29, 588-594.	1.1	37
56	ESHRE Task Force on Ethics and Law 23: medically assisted reproduction in singles, lesbian and gay couples, and transsexual people. Human Reproduction, 2014, 29, 1859-1865.	0.4	128
57	GnRHa trigger for final oocyte maturation: is HCG trigger history?. Reproductive BioMedicine Online, 2014, 29, 274-280.	1.1	45
58	GnRH Agonist Triggers and their Use in Assisted Reproductive Technology: The Past, the Present and the Future. Women's Health, 2014, 10, 267-276.	0.7	12

#	Article	IF	Citations
59	Impact of clomiphene citrate during ovarian stimulation on the luteal phase after GnRH agonist trigger. Reproductive BioMedicine Online, 2014, 28, 359-368.	1.1	5
60	Cumulative success rates following mild IVF in unselected infertile patients: a 3-year, single-centre cohort study. Reproductive BioMedicine Online, 2014, 28, 572-581.	1.1	40
61	GnRH agonist trigger and ovarian hyperstimulation syndrome: relook at â€˜freeze-all strategyâ€™. Reproductive BioMedicine Online, 2014, 29, 392-394.	1.1	52
62	Severe ovarian hyperstimulation syndrome after gonadotropin-releasing hormone (GnRH) agonist trigger and â€œfreeze-allâ€•approach in GnRH antagonist protocol. Fertility and Sterility, 2014, 101, 1008-1011.	0.5	159
63	Clinical rationale for cryopreservation of entire embryo cohorts in lieu of fresh transfer. Fertility and Sterility, 2014, 102, 3-9.	0.5	194
64	Human chorionic gonadotropin vs. gonadotropin-releasing hormone agonist trigger in assisted reproductive technologyâ€”â€œThe king is dead, long live the king!â€• Fertility and Sterility, 2014, 102, 339-341.	0.5	20
65	Cryopreservation and delayed embryo transferâ€“assisted reproductive technology registry and reporting implications. Fertility and Sterility, 2014, 102, 27-31.	0.5	53
66	Progesterone administration for luteal phase deficiency in human reproduction: an old or new issue?. Journal of Ovarian Research, 2015, 8, 77.	1.3	42
67	Ovarian hyperstimulation syndrome in the 21st century. Current Opinion in Obstetrics and Gynecology, 2015, 27, 210-214.	0.9	38
68	Gonadotropin-releasing hormone agonist triggering of oocyte maturation in assisted reproductive technology cycles. Tâ˜ŠÂºrk Jinekoloji Ve Obstetrik Dernei Dergisi, 2015, 12, 96-101.	0.3	4
69	Ovarian hyperstimulation syndrome. InnovAiT, 2015, 8, 531-538.	0.0	1
70	Medroxyprogesterone acetate isÂanÂeffective oral alternative forÂpreventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for inÂvitro fertilization. Fertility and Sterility, 2015, 104, 62-70.e3.	0.5	276
71	Spanish consensus on premature menopause. Maturitas, 2015, 80, 220-225.	1.0	29
72	What is the value of anti-MÃ¼llerian hormone in predicting the response to ovarian stimulation with GnRH agonist and antagonist protocols?. Reproductive Biology and Endocrinology, 2015, 13, 58.	1.4	15
73	Let's not forget that many prepubertal girls do have other options besides ovarian tissue cryopreservation. Human Reproduction, 2015, 30, 2011-2013.	0.4	15
74	Authorsâ€™ reply re: Serum vascular endothelial growth factor levels following luteal gonadotrophinâ€releasing hormone antagonist administration in women with severe early ovarian hyperstimulation syndrome. BJOG: an International Journal of Obstetrics and Gynaecology, 2015, 122, 585-586.	1.1	0
75	Revisiting ovarian hyper stimulation syndrome: Towards OHSS free clinic. Journal of Human Reproductive Sciences, 2015, 8, 13.	0.4	24
76	Freeze-all policy: is it time for that?. Journal of Assisted Reproduction and Genetics, 2015, 32, 171-176.	1.2	103

#	Article	IF	Citations
77	Ovarian hyperstimulation syndrome after gonadotropin-releasing hormone agonist triggering and â€œfreeze-allâ€• in-depth analysis of genetic predisposition. Journal of Assisted Reproduction and Genetics, 2015, 32, 1063-1068.	1.2	30
78	Avoiding ovarian hyperstimulation syndrome with the use of gonadotropin-releasing hormone agonist trigger. Fertility and Sterility, 2015, 103, 870-873.	0.5	54
79	Basic understanding of gonadotropin-releasing hormoneâ€“agonist triggering. Fertility and Sterility, 2015, 103, 867-869.	0.5	38
80	â€˜Luteal coastingâ€™ after GnRH agonist trigger â€“ individualized, HCG-based, progesterone-free luteal support in â€˜high respondersâ€™: a case series. Reproductive BioMedicine Online, 2015, 31, 747-751.	1.1	35
81	A Review of Luteal Support Protocols for Single Embryo Transfers: Fresh and Frozen. , 2015, , 273-293.		0
82	Comprehensive Chromosomal Screening from Polar Body Biopsy to Blastocyst Trophectoderm Sampling: Evidences and Considerations. , 2015, , 89-102.		1
83	Triggering final follicular maturation- hCG, GnRH-agonist or both, when and to whom?. Journal of Ovarian Research, 2015, 8, 60.	1.3	71
85	GnRH Agonist Versus Antagonist in ART. , 2015, , 109-124.		0
88	Does freeze all policy eliminate OHSS??? â€œIt ainâ€™t necessarily soâ€¦â€• Journal of Assisted Reproduction and Genetics, 2015, 32, 1571-1571.	1.2	3
89	Freeze-all at the blastocyst orÂbipronuclear stage: aÂrandomized clinical trial. Fertility and Sterility, 2015, 104, 1138-1144.	0.5	24
90	Sub-optimal responders following controlled ovarian stimulation: an overlooked group?. Human Reproduction, 2015, 30, 2005-2008.	0.4	82
92	The continuum of high ovarian response: a rational approach to the management of high responder patient subgroups. Systems Biology in Reproductive Medicine, 2015, 61, 336-344.	1.0	7
94	Successful Pregnancy Complicated by Adnexal Torsion after IVF in a 45-Year-Old Woman. Gynecology & Obstetrics Case Report, 2016, , .	0.2	0
95	PIVET rFSH dosing algorithms for individualized controlled ovarian stimulation enables optimized pregnancy productivity rates and avoidance of ovarian hyperstimulation syndrome. Drug Design, Development and Therapy, 2016, Volume 10, 2561-2573.	2.0	46
96	The German Middleway as Precursor for Single Embryo Transfer. A Retrospective Data-analysis of the DÃ¼sseldorf University HospitalÊ¼s Interdisciplinary Fertility Centre â€“ UniKiD. Geburtshilfe Und Frauenheilkunde, 2016, 76, 690-698.	0.8	7
97	Segmented ART â€“ The new era in ART?. Reproductive Biology, 2016, 16, 91-103.	0.9	17
98	Anti-MÃ¼llerian Hormone is All You Need: An Assisted Reproductive Technology Perspective in Diagnosing Polycystic Ovary Syndrome. Women's Health, 2016, 12, 263-265.	0.7	1
99	The effectiveness of Hespan in reducing the incidence of severe hyperstimulation syndrome in polycystic ovarian disease patients. Middle East Fertility Society Journal, 2016, 21, 189-193.	0.5	0

#	Article	IF	Citations
100	The effect of an immediate frozen embryo transfer following a freeze-all protocol: a retrospective analysis from two centres. Human Reproduction, 2016, 31, 2541-2548.	0.4	50
101	Maternal and perinatal outcomes after fresh versus frozen embryo transferâ€"what is the risk-benefit ratio?. Fertility and Sterility, 2016, 106, 241-243.	0.5	30
102	Dual trigger for final oocyte maturation improves the oocyte retrieval rate of suboptimal responders to gonadotropin-releasing hormone agonist. Fertility and Sterility, 2016, 106, 1356-1362.	0.5	66
104	Is the type of gonadotropin-releasing hormone suppression protocol for ovarian hyperstimulation associated with ectopic pregnancy in fresh autologous cycles for in vitro fertilization?. Fertility and Sterility, 2016, 106, 666-672.	0.5	16
105	The state of â€œfreeze-for-allâ€•in human ARTs. Journal of Assisted Reproduction and Genetics, 2016, 33, 1543-1550.	1.2	25
106	Oocyte, embryo and blastocyst cryopreservation in ART: systematic review and meta-analysis comparing slow-freezing versus vitrification to produce evidence for the development of global guidance. Human Reproduction Update, 2017, 23, 139-155.	5.2	432
107	An update on the prevention of ovarian hyperstimulation syndrome. Women's Health, 2016, 12, 496-503.	0.7	13
108	Ovarian hyperstimulation syndrome: review and new classification criteria for reporting in clinical trials. Human Reproduction, 2016, 31, 1997-2004.	0.4	118
109	Luteal-Phase Stimulation. ISGE Series, 2016, , 3-10.	0.2	0
110	Optimal endometrial preparation for frozen embryo transfer cycles: window of implantation and progesterone support. Fertility and Sterility, 2016, 105, 867-872.	0.5	121
111	Assisted reproductive techniques after fertility-sparing treatments in gynaecological cancers. Human Reproduction Update, 2016, 22, 281-305.	5.2	46
112	GnRH agonist trigger for the induction of oocyte maturation in GnRH antagonist IVF cycles: a SWOT analysis. Reproductive BioMedicine Online, 2016, 32, 274-285.	1.1	86
113	Monitoring Ovarian Stimulation: Current Perspectives. , 2016, , 17-55.		0
114	What is the optimal duration of progesterone administration before transferring a vitrified-warmed cleavage stage embryo? A randomized controlled trial. Human Reproduction, 2016, 31, 1097-1104.	0.4	55
115	To delay or not to delay a frozen embryo transfer after a failed fresh embryo transfer attempt?. Fertility and Sterility, 2016, 105, 1202-1207.e1.	0.5	34
116	Controlled Ovarian Stimulation Using Medroxyprogesterone Acetate and hMG in Patients With Polycystic Ovary Syndrome Treated for IVF. Medicine (United States), 2016, 95, e2939.	0.4	100
117	Agonist depot versus OCP programming of frozen embryo transfer: a retrospective analysis of freeze-all cycles. Journal of Assisted Reproduction and Genetics, 2016, 33, 207-214.	1.2	21
118	Conventional ovarian stimulation and single embryo transfer for IVF/ICSI. How many oocytes do we need to maximize cumulative live birth rates after utilization of all fresh and frozen embryos?. Human Reproduction, 2016, 31, dev316.	0.4	247

#	Article	IF	Citations
119	A fresh look at the freeze-all protocol: a SWOT analysis. Human Reproduction, 2016, 31, 491-497.	0.4	133
120	GnRH agonist trigger does not always cause luteolysis: a case report. Reproductive BioMedicine Online, 2016, 32, 132-134.	1.1	8
121	Ovarian Stimulation Protocols. , 2016, , .		6
122	Outcomes of GnRH agonist triggering in assisted reproductive technology: a systematic review. Reproducao E Climaterio, 2017, 32, 104-108.	0.1	1
123	Gonadotropin-releasing hormone agonist (GnRHa) trigger â€“ State of the art. Reproductive Biology, 2017, 17, 1-8.	0.9	51
124	Prevention and management of ovarian hyperstimulation syndrome. Thrombosis Research, 2017, 151, S61-S64.	0.8	55
125	The high responder: a review of pathophysiology and outcomes during IVF treatment. Human Fertility, 2017, 20, 155-167.	0.7	13
126	Prediction and Prevention of Ovarian Hyperstimulation Syndrome. , 0, , 124-140.		1
127	Elimination of OHSS by GnRH Agonist and Freezing Embryos. , 0, , 149-163.		4
128	Dual ovarian stimulation and random start in assisted reproductive technologies: from ovarian biology to clinical application. Current Opinion in Obstetrics and Gynecology, 2017, 29, 153-159.	0.9	43
129	Gonadotropin-Releasing Hormoneâ€“Agonist Triggering and a Freeze-All Approach: The Final Step in Eliminating Ovarian Hyperstimulation Syndrome?. Obstetrical and Gynecological Survey, 2017, 72, 296-308.	0.2	19
130	Ovarian hyperstimulation syndrome following GnRH agonist triggerâ€”think ectopic. Journal of Assisted Reproduction and Genetics, 2017, 34, 1161-1165.	1.2	12
131	How many oocytes are optimal toÂachieve multiple live births withÂone stimulation cycle? TheÂone-and-done approach. Fertility and Sterility, 2017, 107, 397-404.e3.	0.5	74
132	Individual luteolysis post GnRH-agonist-trigger in GnRH-antagonist protocols. Gynecological Endocrinology, 2017, 33, 261-264.	0.7	10
133	Fresh versus Frozen Embryo Transfer in PCOS: Arguments for and Against. Seminars in Reproductive Medicine, 2017, 35, 359-363.	0.5	6
134	Frozen embryo transfer: a review on the optimal endometrial preparation and timing. Human Reproduction, 2017, 32, 2234-2242.	0.4	227
135	Comparison of a â€˜freeze-allâ€™ strategy including GnRH agonist trigger versus a â€˜fresh transferâ€™ strategy including hCG trigger in assisted reproductive technology (ART): a study protocol for a randomised controlled trial. BMJ Open, 2017, 7, e016106.	0.8	10
136	GnRH Antagonist Cetrorelix Administration Before hCG for Protection of Ovarian Hyperstimulation Syndrome. Journal of Obstetrics and Gynecology of India, 2017, 67, 270-274.	0.3	3

#	Article	IF	Citations
137	The myths surrounding mild stimulation in vitro fertilization (IVF). Reproductive Biology and Endocrinology, 2017, 15, 48.	1.4	14
138	Freeze-all cycle for all normal responders?. Journal of Assisted Reproduction and Genetics, 2017, 34, 179-185.	1.2	33
139	A direct healthcare cost analysis of the cryopreserved versus fresh transfer policy at the blastocyst stage. Reproductive BioMedicine Online, 2017, 34, 19-26.	1.1	34
140	Gonadotropin-releasing hormone agonist triggering with concomitant administration of low doses of human chorionic gonadotropin or a freeze-all strategy in high responders. Journal of King Abdulaziz University, Islamic Economics, 2017, 38, 586-591.	0.5	5
141	hCG Triggering in ART: An Evolutionary Concept. International Journal of Molecular Sciences, 2017, 18, 1075.	1.8	14
142	Trends over 15 years in ART in Europe: an analysis of 6 million cyclesâ€. Human Reproduction Open, 2017, 2017, hox012.	2.3	88
143	How to personalize ovarian stimulation in clinical practice. Journal of the Turkish German Gynecology Association, 2017, 18, 148-153.	0.2	10
144	GnRH Agonist Triggering of Ovulation Replacing hCG: A 30-Year-Old Revolution in IVF Practice Led by Rambam Health Care Campus. Rambam Maimonides Medical Journal, 2017, 8, e0023.	0.4	1
145	Embryonic Factors Associated with Recurrent Implantation Failure. , 2018, , 59-75.		0
146	Ultrasound and hematological changes during early luteal phase in women at high risk for developing ovarian hyperstimulation syndrome. Ultrasound in Obstetrics and Gynecology, 2018, 51, 126-133.	0.9	8
147	Controlled Ovarian Stimulation for In Vitro Fertilisation Cycles. , 2018, , 259-270.		1
148	PCOS and pregnancy: a review of available therapies to improve the outcome of pregnancy in women with polycystic ovary syndrome. Expert Review of Endocrinology and Metabolism, 2018, 13, 87-98.	1.2	16
149	Pregnancy-related complications and perinatal outcomes resulting from transfer of cryopreserved versus fresh embryos inÂvitro fertilization: a meta-analysis. Fertility and Sterility, 2018, 109, 330-342.e9.	0.5	140
150	Elective frozen-thawed embryo transfer (FET) in women at risk for ovarian hyperstimulation syndrome. Reproductive Biology, 2018, 18, 46-52.	0.9	17
151	Frozen blastocyst transfer outcomes in immediate versus delayed subsequent cycles following GnRH agonist or hCG triggers. Journal of Assisted Reproduction and Genetics, 2018, 35, 669-675.	1.2	28
152	Female fertility preservation: past, present and future. Reproduction, 2018, 156, F11-F27.	1.1	85
153	Live birth rates in the first complete IVF cycle among 20 687 women using a freeze-all strategy. Human Reproduction, 2018, 33, 924-929.	0.4	85
154	GnRHa trigger and luteal coasting: a new approach for the ovarian hyperstimulation syndrome high-risk patient?. Reproductive BioMedicine Online, 2018, 36, 75-77.	1.1	14

#	Article	IF	Citations
155	Number of Oocytes Retrieved as a Criterion for â€œFreeze-Allâ€•Strategy versus a Single â€œRescueâ€•Bolus of Low-Dose Human Chorionic Gonadotropin Following GnRH Agonist for Ovulation Triggering: A Pilot Study. Gynecologic and Obstetric Investigation, 2018, 83, 471-476.	0.7	4
156	Feasibility of corifollitropin alfa/GnRH antagonist protocol combined with GnRH agonist triggering and freeze-all strategy in polycystic ovary syndrome patients. Journal of the Formosan Medical Association, 2018, 117, 535-540.	0.8	24
158	A novel oocyte maturation trigger using 1500ÂIU of human chorionic gonadotropin plus 450ÂIU of follicle-stimulating hormone may decrease ovarian hyperstimulation syndrome across all in vitro fertilization stimulation protocols. Journal of Assisted Reproduction and Genetics, 2018, 35, 297-307.	1.2	9
159	Multiorgan failure associated with severe ovarian hyperstimulation syndrome due to inadequate protocol optimisation: a rare but avoidable complication. BMJ Case Reports, 2018, 2018, bcr-2017-223418.	0.2	4
160	Gonadotropins and Their Analogs: Current and Potential Clinical Applications. Endocrine Reviews, 2018, 39, 911-937.	8.9	39
161	Types and frequency of non-conformances in an IVF laboratory. Human Reproduction, 2018, 33, 2196-2204.	0.4	14
162	Novel Concepts for Inducing Final Oocyte Maturation in In Vitro Fertilization Treatment. Endocrine Reviews, 2018, 39, 593-628.	8.9	92
163	Associations of blastocyst features, trophectoderm biopsy and other laboratory practice with post-warming behavior and implantation. Human Reproduction, 2018, 33, 1992-2001.	0.4	66
165	Cumulative live birth rates according to the number of oocytes retrieved after the first ovarian stimulation for inÂvitro fertilization/intracytoplasmic sperm injection: a multicenter multinational analysis including â^¼15,000 women. Fertility and Sterility, 2018, 110, 661-670.e1.	0.5	243
166	Cumulative live birth rate in freeze-all cycles is comparable to that of a conventional embryo transfer policy at the cleavage stage but superior at the blastocyst stage. Fertility and Sterility, 2018, 110, 703-709.	0.5	27
167	Programming the endometrium for deferred transfer of cryopreserved embryos: hormone replacement versus modified natural cycles. Fertility and Sterility, 2018, 109, 768-774.	0.5	82
168	Luteal phase anovulatory follicles result in the production of competent oocytes: intra-patient paired case-control study comparing follicular versus luteal phase stimulations in the same ovarian cycle. Human Reproduction, 2018, 33, 1442-1448.	0.4	89
169	Luteal Phase Support in IVF/ICSI- and Frozen Embryo Transfer-Cycles. , 2018, , 28-32.		0
170	The Ovulation: Triggering Ovulation with hCG Versus GnRH-Agonist. , 2018, , 263-267.		0
171	Evaluation and Assisted Reproductive Technology of the High Responder Patient. , 2018, , 304-306.		0
172	Luteal Coasting and Individualization of Human Chorionic Gonadotropin Dose after Gonadotropin-Releasing Hormone Agonist Triggering for Final Oocyte Maturationâ€”A Retrospective Proof-of-Concept Study. Frontiers in Endocrinology, 2018, 9, 33.	1.5	11
173	ART in Europe, 2014: results generated from European registries by ESHREâ€. Human Reproduction, 2018, 33, 1586-1601.	0.4	396
174	Of mice and human embryos: is there an ethically preferred order of preclinical research on new assisted reproductive technologies?. Human Reproduction, 2018, 33, 1581-1585.	0.4	3

#	Article	IF	Citations
175	Cumulative live birth rates after IVF in patients with polycystic ovaries: phenotype matters. Reproductive BioMedicine Online, 2018, 37, 163-171.	1.1	47
176	A cost-effectiveness analysis of freeze-only or fresh embryo transfer in IVF of non-PCOS women. Human Reproduction, 2018, 33, 1907-1914.	0.4	34
177	Artificial Cycle with or without a Depot Gonadotropin-releasing Hormone Agonist for Frozen-thawed Embryo Transfer: An Assessment of Infertility Type that Is Most Suitable. Current Medical Science, 2018, 38, 626-631.	0.7	7
178	The Development of In-Vitro Fertilization in Israel. , 0, , 132-140.		0
179	The Development of Ovarian Stimulation for In-Vitro Fertilization. , 0, , 202-207.		1
180	Ovulation Induction With Gonadotropins. , 2019, , 570-580.		0
181	Assisted Reproduction. , 2019, , 779-822.e16.		5
182	A Rationale for Timing of Luteal Support Post Gonadotropin-Releasing Hormone Agonist Trigger. Gynecologic and Obstetric Investigation, 2019, 84, 1-5.	0.7	7
183	Is oocyte maturation rate associated with triptorelin dose used for triggering final oocyte maturation in patients at high risk for severe ovarian hyperstimulation syndrome?. Human Reproduction, 2019, 34, 1770-1777.	0.4	6
184	The Freeze-All Cycle: A New Paradigm Shift in ART. , 2019, , 765-778.		3
185	Repeated GnRH agonist doses for luteal support: a proof of concept. Reproductive BioMedicine Online, 2019, 39, 770-776.	1.1	9
186	Obstetric and neonatal outcome of ART in patients with polycystic ovary syndrome: IVM of oocytes versus controlled ovarian stimulation. Human Reproduction, 2019, 34, 1595-1607.	0.4	42
187	A meta-analysis of pregnancy-related outcomes and complications in women with polycystic ovary syndrome undergoing IVF. Reproductive BioMedicine Online, 2019, 39, 281-293.	1.1	109
188	The number of oocytes associated with maximum cumulative live birth rates per aspiration depends on female age: a population study of 221â€‰221 treatment cycles. Human Reproduction, 2019, 34, 1778-1787.	0.4	54
189	In vitro maturation for expected high responders: balancing the effectiveness and safety. Human Reproduction, 2019, 34, 2080-2080.	0.4	0
190	A quality management approach to controlled ovarian stimulation in assisted reproductive technology: the "Fischer protocol". Panminerva Medica, 2019, 61, 11-23.	0.2	35
191	Freeze-all strategy in IVF/ICSI cycles: an update on clinical utility. Panminerva Medica, 2019, 61, 52-57.	0.2	20
192	Advances in ovulation trigger strategies. Panminerva Medica, 2019, 61, 42-51.	0.2	18

#	Article	IF	Citations
193	Early onset of cabergoline therapy for prophylaxis from ovarian hyperstimulation syndrome (OHSS): A potentially safer and more effective protocol. Reproductive Biology, 2019, 19, 145-148.	0.9	8
194	In Freeze-All Strategy, Cumulative Live Birth Rate (CLBR) Is Increasing According to the Number of Blastocysts Formed in Women <40 Undergoing Intracytoplasmic Sperm Injection (ICSI). Frontiers in Endocrinology, 2019, 10, 427.	1.5	14
195	Breakthroughs and challenges of modern developmental biology and reproductive medicine. International Journal of Developmental Biology, 2019, 63, 77-82.	0.3	1
196	Ovarian response in oocyte donation cycles under LH suppression with GnRH antagonist or desogestrel progestin: retrospective and comparative study. Gynecological Endocrinology, 2019, 35, 884-889.	0.7	11
197	A Second Dose of GnRHa in Combination with Luteal GnRH Antagonist May Eliminate Ovarian Hyperstimulation Syndrome in Women with â‰¥30 Follicles Measuring â‰¥11 mm in Diameter on Trigger Day and/or Pre-trigger Peak Estradiol Exceeding 10 000 pg/mL. Current Medical Science, 2019, 39, 278-284.	0.7	5
198	Longâ€term outcomes of freezeâ€all strategy: A retrospective analysis from a single ART center in Japan. Reproductive Medicine and Biology, 2019, 18, 173-179.	1.0	9
199	Cumulative live birth rates following a â€˜freeze-allâ€™ strategy: a population-based study. Human Reproduction Open, 2019, 2019, hoz004.	2.3	26
200	Patientsâ€™ attitudes and preferences towards a freeze-all strategy in ART treatment. Human Reproduction, 2019, 34, 679-688.	0.4	38
201	A predictive formula for selecting individual FSH starting dose based on ovarian reserve markers in IVF/ICSI cycles. Archives of Gynecology and Obstetrics, 2019, 300, 441-446.	0.8	7
202	Use of progestins to inhibit spontaneous ovulation during ovarian stimulation: the beginning of a new era?. Reproductive BioMedicine Online, 2019, 39, 321-331.	1.1	51
203	Prediction of live birth and cumulative live birth rates in freeze-all-IVF treatment of a general population. Journal of Assisted Reproduction and Genetics, 2019, 36, 685-696.	1.2	16
204	The Gonadotropins in IVF. , 2019, , 69-79.		0
205	On The Strategy of â€œFreezing Onlyâ€•Embryos. , 2019, , 354-361.		0
206	Advanced Maternal Age in IVF: Still a Challenge? The Present and the Future of Its Treatment. Frontiers in Endocrinology, 2019, 10, 94.	1.5	103
207	Live birth rates and perinatal outcomes when all embryos are frozen compared with conventional fresh and frozen embryo transfer: a cohort study of 337,148 in vitro fertilisation cycles. BMC Medicine, 2019, 17, 202.	2.3	19
208	Knowledge and attitudes of subfertile couples towards disposition of supernumerary cryopreserved embryos: an Indian perspective. Reproductive Biomedicine and Society Online, 2019, 9, 11-16.	0.9	1
209	Should we still perform fresh embryo transfers in ART?. Human Reproduction, 2019, 34, 2319-2329.	0.4	31
210	Fresh versus elective frozen embryo transfer in IVF/ICSI cycles: a systematic review and meta-analysis of reproductive outcomes. Human Reproduction Update, 2019, 25, 2-14.	5.2	307

#	Article	IF	Citations
211	In vitro fertilisation/intracytoplasmic sperm injection beyond 2020. BJOG: an International Journal of Obstetrics and Gynaecology, 2019, 126, 237-243.	1.1	38
212	Endogenous progesterone levels could predict reproductive outcome in frozen embryo replacement cycles supplemented with synthetic progestogens: A retrospective cohort study. Reproductive Medicine and Biology, 2019, 18, 91-96.	1.0	9
213	Luteal phase support with GnRH agonist does not eliminate the risk for ovarian hyperstimulation syndrome. Gynecological Endocrinology, 2019, 35, 368-369.	0.7	8
214	Individualization of the starting dose of follitropin delta reduces the overall OHSS risk and/or the need for additional preventive interventions: cumulative data over three stimulation cycles. Reproductive BioMedicine Online, 2019, 38, 528-537.	1.1	33
215	Live birth rate and neonatal outcome following cleavage-stage embryo transfer versus blastocyst transfer using the freeze-all strategy. Reproductive BioMedicine Online, 2019, 38, 892-900.	1.1	20
216	Towards complication-free assisted reproduction technology. Best Practice and Research in Clinical Endocrinology and Metabolism, 2019, 33, 9-19.	2.2	5
217	Ovarian Hyperstimulation Syndrome. , 2019, , 345-362.		3
218	The endometrium during and after ovarian hyperstimulation and the role of segmentation of infertility treatment. Best Practice and Research in Clinical Endocrinology and Metabolism, 2019, 33, 61-75.	2.2	20
220	Association between body mass index and oocyte maturation in patients triggered with GnRH agonist who are at high risk for severe ovarian hyperstimulation syndrome: an observational cohort study. Reproductive BioMedicine Online, 2020, 40, 168-175.	1.1	9
221	Large-for-gestational age is male-gender dependent in artificial frozen embryo transfers cycles: a cohort study of 1295 singleton live births. Reproductive BioMedicine Online, 2020, 40, 134-141.	1.1	14
222	Delayed frozen embryo transfer failed to improve live birth rate and neonatal outcomes in patients requiring whole embryo freezing. Reproductive Biology and Endocrinology, 2020, 18, 1.	1.4	54
223	Ovarian stimulation for freeze-all IVF cycles: a systematic review. Human Reproduction Update, 2020, 26, 119-136.	5.2	62
224	Clinical utility of freeze-all approach in ART treatment: A mini-review. Cryobiology, 2020, 92, 9-14.	0.3	19
225	Higher estradiol levels are associated with lower neonatal birthweight after fresh and frozen embryo transfers. A cohort study of 3631 singleton IVF pregnancies. Gynecological Endocrinology, 2021, 37, 618-623.	0.7	12
226	Early pregnancy loss in patients with polycystic ovary syndrome after IVM versus standard ovarian stimulation for IVF/ICSI. Human Reproduction, 2020, 35, 2763-2773.	0.4	5
227	Elective frozen embryo transfer (freeze-all): there seems to be no harm to transfer in the next immediate menstrual cycle. Annals of Translational Medicine, 2020, 8, 913-913.	0.7	2
228	Freeze-all versus fresh blastocyst transfer strategy during in vitro fertilisation in women with regular menstrual cycles: multicentre randomised controlled trial. BMJ, The, 2020, 370, m2519.	3.0	80
229	GnRH agonist triggering followed by 1500 IU of HCG 48 h after oocyte retrieval for luteal phase support. Reproductive BioMedicine Online, 2020, 41, 854-858.	1.1	6

#	Article	IF	Citations
230	Medroxyprogesterone acetate used in ovarian stimulation is associated with reduced mature oocyte retrieval and blastocyst development: a matched cohort study of 825 freeze-all IVF cycles. Journal of Assisted Reproduction and Genetics, 2020, 37, 2337-2345.	1.2	3
231	A freeze-all strategy does not increase live birth rates in women of advanced reproductive age. Journal of Assisted Reproduction and Genetics, 2020, 37, 2443-2451.	1.2	5
232	Outcome of in-vitro oocyte maturation in patients with PCOS: does phenotype have an impact?. Human Reproduction, 2020, 35, 2272-2279.	0.4	16
233	The freeze-all strategy versus agonist triggering with low-dose hCG for luteal phase support in IVF/ICSI for high responders: a randomized controlled trial. Human Reproduction, 2020, 35, 2808-2818.	0.4	27
234	Should we still offer elective freezing of all embryos in all IVF cycles?. Human Reproduction, 2020, 35, 2179-2184.	0.4	8
235	To delay or not frozen embryo transfer in freeze-all cycles?. Annals of Translational Medicine, 2020, 8, 812-812.	0.7	0
236	Randomized, assessor-blinded trial comparing highly purified human menotropin and recombinant follicle-stimulating hormone in high responders undergoing intracytoplasmic sperm injection. Fertility and Sterility, 2020, 114, 321-330.	0.5	25
237	Gonadotropin-releasing hormone agonist for ovulation trigger â€“ OHSS prevention and use of modified luteal phase support for fresh embryo transfer. Upsala Journal of Medical Sciences, 2020, 125, 131-137.	0.4	18
238	Vitrification and the demise of fresh treatment cycles in ART. Reproductive BioMedicine Online, 2020, 41, 217-224.	1.1	15
239	When is the optimal timing of frozen embryo transfer after controlled ovarian stimulation?. Annals of Translational Medicine, 2020, 8, 425-425.	0.7	2
240	The performance of the ElecsysÂ® anti-MÃ¼llerian hormone assay in predicting extremes of ovarian response to corifollitropin alfa. Reproductive BioMedicine Online, 2020, 41, 29-36.	1.1	7
241	In Vitro Maturation and Fertilization of Oocytes: From Laboratory Bench to Clinical Practice. , 0, , .		0
243	A decision-making algorithm for performing or cancelling embryo transfer in patients at high risk for ovarian hyperstimulation syndrome after triggering final oocyte maturation with hCG. Human Reproduction Open, 2020, 2020, hoaa013.	2.3	5
244	Frozen-warmed blastocyst transfer after 6 or 7 days of progesterone administration: impact on live birth rate in hormone replacement therapy cycles. Fertility and Sterility, 2020, 114, 125-132.	0.5	19
245	EStradiol and PRogesterone in In vitro ferTilization (ESPRIT): a multicenter study evaluating third- versus second-generation estradiol and progesterone immunoassays. Journal of Endocrinological Investigation, 2020, 43, 1239-1248.	1.8	3
246	The ART of frozen embryo transfer: back to nature!. Gynecological Endocrinology, 2020, 36, 479-483.	0.7	33
247	Treatment update for anovulation and subfertility in polycystic ovary syndrome. Current Opinion in Endocrine and Metabolic Research, 2020, 12, 53-58.	0.6	2
248	The effect of type of oral contraceptive pill and duration of use on fresh and cumulative live birth rates in IVF/ICSI cycles. Human Reproduction, 2020, 35, 826-836.	0.4	14

#	Article	IF	Citations
249	Factors associated with serum progesterone concentrations the day before cryopreserved embryo transfer in artificial cycles. Reproductive BioMedicine Online, 2020, 40, 797-804.	1.1	39
250	Equivalent live-birth rate in antagonist IVF/ICSI protocol after oocyte triggering with GnRH agonist supplemented with 1500 r-hCG the day of oocyte retrieval vs r-hCG : A case-control study. Journal of Gynecology Obstetrics and Human Reproduction, 2020, 49, 101702.	0.6	0
251	The Future of Cryopreservation in Assisted Reproductive Technologies. Frontiers in Endocrinology, 2020, 11, 67.	1.5	62
252	Severe early-onset ovarian hyperstimulation syndrome with liver dysfunction in an IVF segmentation cycle. BMJ Case Reports, 2020, 13, e233379.	0.2	2
253	COVID-19 and ART: the view of the Italian Society of Fertility and Sterility and Reproductive Medicine. Reproductive BioMedicine Online, 2020, 40, 755-759.	1.1	47
254	Freeze-all, for whom, when, and how. Upsala Journal of Medical Sciences, 2020, 125, 104-111.	0.4	8
255	Is ovarian response associated with adverse perinatal outcomes in GnRH antagonist IVF/ICSI cycles?. Reproductive BioMedicine Online, 2020, 41, 263-270.	1.1	8
256	A prospective study of oral estrogen versus transdermal estrogen (gel) for hormone replacement frozen embryo transfer cycles. Gynecological Endocrinology, 2021, 37, 515-518.	0.7	5
257	Is there an optimal number of oocytes retrieved at which live birth rates or cumulative live birth rates per aspiration are maximized after ART? A systematic review. Reproductive BioMedicine Online, 2021, 42, 83-104.	1.1	27
258	Gonadotropin-releasing hormone analogs: Mechanisms of action and clinical applications in female reproduction. Frontiers in Neuroendocrinology, 2021, 60, 100876.	2.5	11
259	Oral dydrogesterone vs. micronized vaginal progesterone gel for luteal phase support in frozen-thawed single blastocyst transfer in good prognosis patients. Journal of Gynecology Obstetrics and Human Reproduction, 2021, 50, 102030.	0.6	19
260	The freeze-all strategy after IVF: which indications?. Reproductive BioMedicine Online, 2021, 42, 529-545.	1.1	25
261	Transfer of fresh or frozen embryos: a randomised controlled trial. Human Reproduction, 2021, 36, 998-1006.	0.4	27
262	Endometrial Receptivity Analysis (ERA): data versus opinions. Human Reproduction Open, 2021, 2021, hoab011.	2.3	41
263	Metaâ€analysis of the embryo freezing transfer interval. Reproductive Medicine and Biology, 2021, 20, 144-158.	1.0	9
264	Cost-effectiveness of freeze-all policy â€“ A retrospective study based upon the outcome of cumulative live births. Taiwanese Journal of Obstetrics and Gynecology, 2021, 60, 125-131.	0.5	4
266	A Comparison of the Efficacy of Immediate Versus Delayed Frozenâ€“Thawed Embryo Transfer on the Ongoing Pregnancy Rate After a Failed IVF Attempt: Study Protocol for a Randomized, Non-Inferiority, Parallel-Group, Controlled Trial. Frontiers in Endocrinology, 2021, 12, 603158.	1.5	2
267	Fresh versus frozen embryo transfers in assisted reproduction. The Cochrane Library, 2021, 2021, CD011184.	1.5	48

#	Article	IF	Citations
268	Warrants of cryopreservation in assisted reproductive technology amidst COVID-19 pandemic. , 0, 2, 49-54.		0
270	Luteal Support with very Low Daily Dose of Human Chorionic Gonadotropin after Fresh Embryo Transfer as an Alternative to Cycle Segmentation for High Responders Patients Undergoing Gonadotropin-Releasing Hormone Agonist-Triggered IVF. Pharmaceuticals, 2021, 14, 228.	1.7	2
271	Individualized Luteal Phase Support. , 2021, , 39-49.		0
272	Oocyte competence is independent of the ovulation trigger adopted: a large observational study in a setting that entails vitrified-warmed single euploid blastocyst transfer. Journal of Assisted Reproduction and Genetics, 2021, 38, 1419-1427.	1.2	9
273	Pasado presente y futuro de la estimulaciÃ³n ovÃ¡rica en el tratamiento de la infertilidad. Revista MÃ©dica ClÃ¬nica Las Condes, 2021, 32, 173-179.	0.2	1
275	Safety of OvaleapÂ® (Follitropin Alfa) in Infertile Women Undergoing Superovulation for Assisted Reproductive Technologies: A Multinational Comparative, Prospective Cohort Study. Frontiers in Endocrinology, 2021, 12, 632674.	1.5	2
276	Individualised luteal phase support in artificially prepared frozen embryo transfer cycles based on serum progesterone levels: a prospective cohort study. Human Reproduction, 2021, 36, 1552-1560.	0.4	60
277	Fertility outcomes in women after controlled ovarian stimulation with gonadotropin releasing hormone agonist long protocol: fresh versus frozen embryo transfer. BMC Pregnancy and Childbirth, 2021, 21, 207.	0.9	4
278	Embryo Morphokinetics and Blastocyst Development After GnRH Agonist versus hCG Triggering in Normo-ovulatory Women: a Secondary Analysis of a Multicenter Randomized Controlled Trial. Reproductive Sciences, 2021, 28, 2972-2981.	1.1	2
279	Optimising Follicular Development, Pituitary Suppression, Triggering and Luteal Phase Support During Assisted Reproductive Technology: A Delphi Consensus. Frontiers in Endocrinology, 2021, 12, 675670.	1.5	21
280	Low dose hCG supplementation in a Gn-RH-agonist trigger protocol is associated with worse pregnancy outcomes: a retrospective cohort study. Fertility Research and Practice, 2021, 7, 12.	4.1	2
281	Dose adjustment of follicle-stimulating hormone (FSH) during ovarian stimulation as part of medically-assisted reproduction in clinical studies: a systematic review covering 10 years (2007â€“2017). Reproductive Biology and Endocrinology, 2021, 19, 68.	1.4	18
282	Timing of Embryo Culture. , 2021, , 66-74.		0
284	A randomised, multi-center, open trial comparing a semi-automated closed vitrification system with a manual open system in women undergoing IVF. Human Reproduction, 2021, 36, 2101-2110.	0.4	6
285	The Maribor consensus: report of an expert meeting on the development of performance indicators for clinical practice in ART. Human Reproduction Open, 2021, 2021, hoab022.	2.3	29
287	The exogenous progesterone-free luteal phase: two pilot randomized controlled trials in IVF patients. Reproductive BioMedicine Online, 2021, 42, 1108-1118.	1.1	5
288	Molecular Mechanism and Prevention Strategy of Chemotherapy- and Radiotherapy-Induced Ovarian Damage. International Journal of Molecular Sciences, 2021, 22, 7484.	1.8	34
289	Impact of Plasmatic Progesterone on the Day of Frozen Embryo Transfer in Hormone-induced Cycles. Revista Brasileira De Ginecologia E Obstetricia, 2021, 43, 608-615.	0.3	1

#	Article	IF	Citations
290	Immediate versus delayed frozen embryo transfer in women following a failed IVF-ET attempt: a multicenter randomized controlled trial. Reproductive Biology and Endocrinology, 2021, 19, 131.	1.4	7
291	Age-specific effect of fresh versus frozen embryo transfer on fetal anomalies or intrauterine growth restriction rate. Taiwanese Journal of Obstetrics and Gynecology, 2021, 60, 831-835.	0.5	0
292	International Committee for Monitoring Assisted Reproductive Technologies (ICMART): world report on assisted reproductive technologies, 2013. Fertility and Sterility, 2021, 116, 741-756.	0.5	27
293	A randomized Clinical Trial comparing embryo quality and clinical pregnancy rate in PCOS patients underwent controlled ovarian stimulation using antagonist protocol with freeze all strategy and triggered for final oocyte maturation by gonadotropin agonist versus human chorionic gonadotropin in IVF cycles. Obstetrics & Gynecology International Journal, 2021, 12, 279-282.	0.0	0
294	GnRH Antagonist-Based Protocols for In Vitro Fertilization. Methods in Molecular Biology, 2014, 1154, 289-304.	0.4	10
295	Current Therapeutic Options for Controlled Ovarian Stimulation in Assisted Reproductive Technology. Drugs, 2020, 80, 973-994.	4.9	17
296	Does the interval between the last GnRH antagonist dose and the GnRH agonist trigger affect oocyte recovery and maturation rates?. Reproductive BioMedicine Online, 2020, 41, 917-924.	1.1	4
297	Prediction of Ovarian Hyperstimulation Syndrome in Patients Treated with Corifollitropin alfa or rFSH in a GnRH Antagonist Protocol. PLoS ONE, 2016, 11, e0149615.	1.1	73
298	Individual luteolysis pattern after GnRH-agonist trigger for final oocyte maturation. PLoS ONE, 2017, 12, e0176600.	1.1	21
299	COMFFETI, Combined Fresh and Frozen Embryo Transfers per Individual: A New Index of Quality Control for The Performance of emberyologic Labs in The Emerging Era of Segmentation of Cycle and Freeze-All Strategy. International Journal of Fertility & Sterility, 2019, 12, 339-342.	0.2	3
300	GnRH agonist trigger versus hCG trigger in GnRH antagonist in IVF/ICSI cycles: A review article. International Journal of Reproductive BioMedicine, 2016, 14, 557-566.	0.5	22
301	Hematocrit as a simple method to predict and manage ovarian hyperstimulation syndrome in assisted reproduction. Journal of Human Reproductive Sciences, 2015, 8, 93.	0.4	2
302	Early onset ovarian hyperstimulation syndrome despite use of segmentation approach and ovarian hyperstimulation syndrome prophylaxis. Journal of Human Reproductive Sciences, 2015, 8, 234.	0.4	14
303	Gonadotropin-releasing hormone agonist trigger is a better alternative than human chorionic gonadotropin in PCOS undergoing IVF cycles for an OHSS Free Clinic: A Randomized control trial. Journal of Human Reproductive Sciences, 2016, 9, 164.	0.4	25
304	Repeat dose of gonadotropin-releasing hormone agonist trigger in polycystic ovarian syndrome undergoing In Vitro fertilization cycles provides a better cycle outcome - a proof-of-concept study. Journal of Human Reproductive Sciences, 2017, 10, 271.	0.4	7
305	Severe Early-onset Ovarian Hyperstimulation Syndrome following Use of GnRH Agonist Trigger along with Low-dose hCG. International Journal of Infertility and Fetal Medicine, 2016, 7, 68-72.	0.0	2
306	Cost-Effectiveness of the Freeze-All Policy. Jornal Brasileiro De Reproducao Assistida, 2015, 19, 125-130.	0.3	37
307	Freeze-all cycle in reproductive medicine: current perspectives. Jornal Brasileiro De Reproducao Assistida, 2017, 21, 49-53.	0.3	46

#	Article	IF	Citations
308	Clinical Pregnancy and Incidence of Ovarian Hyperstimulation Syndrome in High Ovarian Responders Receiving Different Doses of hCG Supplementation in a GnRH-Agonist Trigger Protocol. Evidence-based Complementary and Alternative Medicine, 2021, 2021, 1-7.	0.5	4
309	Clinical, obstetric and perinatal outcomes after vitrified-warmed euploid blastocyst transfer are independent of cryo-storage duration. Reproductive BioMedicine Online, 2022, 44, 221-227.	1.1	7
310	Ovarian Hyperstimulation: Diagnosis, Prevention, and Management. Seminars in Reproductive Medicine, 2021, 39, 170-179.	0.5	4
311	Gonadotropin-Releasing Hormone (GnRH) Agonist Trigger in a GnRH Antagonist Protocol and Severe Ovarian Hyperstimulation Syndrome. British Journal of Medicine and Medical Research, 2015, 5, 1188-1192.	0.2	1
312	Outcomes of fresh or frozen single blastocyst transfer: comparative study. Russian Journal of Human Reproduction, 2015, 21, 66.	0.1	1
313	Polycystic Ovarian Syndrome and Response to Stimulation. , 2015, , 329-345.		0
314	In Vitro Matitration of oocytes. Indication, technique and results. Russian Journal of Human Reproduction, 2015, 21, 32.	0.1	4
315	1 Ethiek van de voortplantingsgeneeskunde. , 2016, , 21-69.		0
316	Standard Ovarian Stimulation Protocols and Their Outcomes. , 2017, , 129-146.		0
317	Elective freeze-all embryos: What is the scientific evidence?. Australasian Medical Journal, 2017, 10, .	0.1	0
318	Polar Body, Cleavage Stage and Trophectoderm Biopsy. , 2017, , 245-258.		0
319	Modern approaches to the use of gonadotropin-releasing hormone agonists of assisted reproductive technologies. Russian Journal of Human Reproduction, 2018, 24, 75.	0.1	0
320	Retrospective Study to Compare Frozen-Thawed Embryo Transfer with Fresh Embryo Transfer on Pregnancy Outcome Following Intracytoplasmic Sperm Injection for Male Infertility. Medical Science Monitor, 2018, 24, 2668-2674.	0.5	9
321	Perinatal outcomes following assisted reproductive technology. Journal of Human Reproductive Sciences, 2019, 12, 177.	0.4	5
322	Estudio del fallo repetido de implantaciÃ³n y sus posibles alternativas terapÃ©uticas (2017). Progresos En Obstetricia Y Ginecologia, 2019, , .	0.0	0
323	Reproductive medicine: ethical reflections. , 2019, , 27-50.		0
324	HORMONAL SUPPORT OF ENDOMETRIUM IN IVF CYCLES WITH VITRIFIED EUPLOID BLASTOCYST TRANSFER. Problemi Endokrinnoi Patologii, 2019, 69, 35-41.	0.0	0
325	Fresh Versus Frozen Embryo Transfer. , 2020, , 279-287.		0

#	Article	IF	Citations
326	Triggering Final Follicular Maturation for IVF Cycles. , 2020, , 141-150.		0
327	IVM in patients with high risk of OHSS. Russian Journal of Human Reproduction, 2020, 26, 47.	0.1	0
330	Frozen embryo transfer after PGT-A cycles: To wait or not to wait?. Medicina Reproductiva Y EmbriologÃa ClÃnica, 2020, 7, 83-88.	0.1	0
331	In Vitro Fertilization for Polycystic Ovarian Syndrome. Clinical Obstetrics and Gynecology, 2021, 64, 39-47.	0.6	1
332	IVF and the exogenous progesterone-free luteal phase. Current Opinion in Obstetrics and Gynecology, 2021, 33, 188-195.	0.9	2
333	Severe ovarian hyperstimulation syndrome and gonadotropin-releasing hormone agonist trigger in patients with hypogonadotropic hypogonadism: A report of two cases. TâˆšÂºrk Jinekoloji Ve Obstetrik Dernei Dergisi, 2020, 17, 314-317.	0.3	0
334	Elective frozen embryo transfer â€“ What is the evidence?. The Onco Fertility Journal, 2020, 3, 7.	0.3	0
335	AMH and Medically Assisted Reproduction. , 2020, , 31-36.		0
336	Cryopreservation of Human Embryos: Basic Principles and Current Considerations. , 2020, , 505-514.		0
337	Polycystic Ovarian Syndrome and Medically Assisted Reproduction. , 2020, , 241-248.		2
338	Rare occurrence of spontaneous ovarian hyperstimulation syndrome in frozen-thawed embryo transfer cycle resulting in healthy twin birth. The Onco Fertility Journal, 2020, 3, 32.	0.3	0
339	Clinical factors that affect the pregnancy rate in frozen-thawed embryo transfer in the freeze-all policy. Yeungnam University Journal of Medicine, 2020, 37, 47-53.	0.7	1
340	HCG trigger versus GnRH agonist trigger in PCOS patients undergoing IVF cycles: frozen embryo transfer outcomes. Jornal Brasileiro De Reproducao Assistida, 2020, 25, 48-58.	0.3	3
341	Outpatient Management of Severe Ovarian Hyperstimulation Syndromeâ€ˆ(OHSS) with Placement of Pigtail Catheter. Facts, Views & Vision in ObGyn, 2014, 6, 31-7.	0.5	3
342	IVM results are comparable and may have advantages over standard IVF. Facts, Views & Vision in ObGyn, 2014, 6, 77-80.	0.5	22
343	A new approach for ovarian stimulation in IVF using Corifollitropin Alfa in combination with GnRH analogues to trigger final oocyte maturation. A pilot study. Facts, Views & Vision in ObGyn, 2014, 6, 159-65.	0.5	8
344	The Luteal Phase after GnRHa Trigger-Understanding An Enigma. International Journal of Fertility & Sterility, 2014, 8, 227-34.	0.2	13
345	Comparison of hCG triggering versus hCG in combination with a GnRH agonist: a prospective randomized controlled trial. Facts, Views & Vision in ObGyn, 2014, 6, 203-9.	0.5	19

#	Article	IF	Citations
346	GnRH agonist trigger versus hCG trigger in GnRH antagonist in IVF/ICSI cycles: A review article. International Journal of Reproductive BioMedicine, 2016, 14, 557-566.	0.5	11
347	Correlation between sonographic follow-up of follicular growth, serum and salivary estradiol in women undergoing controlled ovarian stimulation (IVF/ICSI). Facts, Views & Vision in ObGyn, 2018, 10, 173-179.	0.5	0
348	Targeting infertility in PCOS: Unfolding â€œAriadne's threadâ€•, 2022, , 153-165.		0
349	Cumulative live birth rate after ovarian stimulation with freeze-all in women with polycystic ovaries: does the polycystic ovary syndrome phenotype have an impact?. Reproductive BioMedicine Online, 2022, 44, 565-571.	1.1	2
350	The Freezing of All Embryos Should Be Used for All IVF Cycles. , 2021, , 84-86.		0
351	Does the freeze-all strategy improve the cumulative live birth rate and the time to become pregnant in IVF cycles?. Archives of Gynecology and Obstetrics, 2022, 305, 1203-1213.	0.8	2
354	Dydrogesterone supplementation in addition to routine micronized progesterone administration for luteal support in cycles triggered with lone GnRH agonist results in an acceptable pregnancy rate and avoids the need to freeze embryos. Minerva Obstetrics and Gynecology, 2023, 75, .	0.5	2
355	Frozen Blastocyst Embryo Transfer: Comparison of Protocols and Factors Influencing Outcome. Journal of Clinical Medicine, 2022, 11, 737.	1.0	9
356	Elective freezing of embryos versus fresh embryo transfer in IVF: a multicentre randomized controlled trial in the UK (E-Freeze). Human Reproduction, 2022, 37, 476-487.	0.4	23
357	Clinical efficacy of dual trigger with human chorionic gonadotropin and a gonadotropinâ€releasing hormone agonist for women undergoing fertility preservation. Reproductive Medicine and Biology, 2022, 21, e12440.	1.0	2
358	The effect of extended cryo-storage following vitrification on embryo competence: a systematic review and meta-analysis. Journal of Assisted Reproduction and Genetics, 2022, 39, 873-882.	1.2	10
359	Clinical outcomes of sildenafil application in patients of poor endometrial development. Gynecology and Obstetrics Clinical Medicine, 2022, 2, 14-19.	0.2	0
360	IVF and human evolution. Human Reproduction Update, 2022, 28, 457-479.	5.2	6
361	The effect of dual stimulation on ploidy rates in patients with poor ovarian response. Journal of Surgery and Medicine, 2021, 5, 1139-1143.	0.0	0
362	Artificially prepared vitrifiedâ€“warmed embryo transfer cycles are associated with an increased risk of pre-eclampsia. Reproductive BioMedicine Online, 2022, 44, 915-922.	1.1	6
363	The Use of GnRH Agonists to Trigger Final Oocyte Maturation during Controlled Ovarian Stimulation. , 2022, , 282-289.		0
364	The Case against Mild Stimulation Protocols. , 2022, , 47-54.		0
365	Polycystic Ovary Syndrome: Controlled Ovarian Stimulation. , 2022, , 132-140.		0

#	Article	IF	Citations
366	Immediate versus postponed single blastocyst transfer in modified natural cycle frozen embryo transfer (mNC-FET): a study protocol for a multicentre randomised controlled trial. BMJ Open, 2021, 11, e053234.	0.8	0
367	COMPARISON OF A 'FREEZE-ALL' STRATEGY VERSUS A 'FRESH TRANSFER' STRATEGY AMONG POOR RESPONDERS IN ASSISTED REPRODUCTIVE TECHNOLOGY (ART). , 2022, , 40-42.		0
368	A comparison of frozen-thawed embryo transfer protocols in 2920 single-blastocyst transfers. Archives of Gynecology and Obstetrics, 2022, , 1.	0.8	2
369	Medroxyprogesterone Acetate versus Gonadotropin-Releasing Hormone Antagonist for the Prevention of Premature Luteinizing Hormone Surge in hyper-responder women undergoing controlled ovarian stimulation for IVF/ICSI Cycles. Jornal Brasileiro De Reproducao Assistida, 2022, , .	0.3	1
370	Pro: Fresh versus frozen embryo transfer. Is frozen embryo transfer the future?. Human Reproduction, 2022, 37, 1379-1387.	0.4	5
371	Extended culture of cleavage embryo to blastocyst embryo is among the good predictors of successful outcome in vitrified-thawed ICSI cycles. Middle East Fertility Society Journal, 2022, 27, .	0.5	0
372	Reproductive, obstetric, and long-term health outcome after uterus transplantation: results of the first clinical trial. Fertility and Sterility, 2022, 118, 576-585.	0.5	19
373	General infertility workup in times of high assisted reproductive technology efficacy. Fertility and Sterility, 2022, 118, 8-18.	0.5	4
374	Freeze-all policy versus luteal phase support with low dose of human chorionic gonadotrophin for high-responder patients undergoing intracytoplasmic sperm injection on pregnancy outcomes: a retrospective cohort observational study. Middle East Fertility Society Journal, 2022, 27, .	0.5	0
376	Effect of long-term embryo cryopreservation on subsequent frozen embryo transfer outcomes: A retrospective cohort study. Journal of Human Reproductive Sciences, 2022, 15, 293.	0.4	0
377	Ovarian stimulation in assisted reproductive technology cycles for varied patient profiles: An Indian perspective. Journal of Human Reproductive Sciences, 2022, 15, 112.	0.4	2
379	The in-vitro effect of gonadotropinsâ€™ type and combination on Granulosa cells gene expressions. Reproductive Biology and Endocrinology, 2022, 20, .	1.4	1
383	Risk of Hypertensive Disorders in Pregnancy After Fresh and Frozen Embryo Transfer in Assisted Reproduction: A Population-Based Cohort Study With Within-Sibship Analysis. Hypertension, 2023, 80, .	1.3	11
384	Comparison of blastocyst euploidy rates following luteal versus follicular phase stimulation in a GnRH antagonist protocol: a prospective study with repeated ovarian stimulation cycles. Human Reproduction, 2022, 37, 2777-2786.	0.4	4
385	Ovarian hyperstimulation syndrome following the use of GnRH agonist trigger of final oocyte maturation and freeze-all strategy: A case report and review of the literature. Asian Pacific Journal of Reproduction, 2022, 11, 292.	0.2	0
386	Prolong cryopreservation duration negatively affects pregnancy outcomes of vitrified-warmed blastocyst transfers using an open-device system: A retrospective cohort study. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2023, 281, 68-75.	0.5	2
387	Cetrorelix in reproductive medicine. F&S Reports, 2023, 4, 62-64.	0.4	1
388	Live birth is not the only relevant outcome in research assessing assisted reproductive technology. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2023, 86, 102306.	1.4	3

#	Article	IF	Citations
389	To freeze or not to freeze, what is the answer?. Fertility and Sterility, 2023, 119, 195.	0.5	0
390	Ovarian Hyperstimulation Syndrome (OHSS) requiring Intensive Care Unit (ICU) admission between 1996-2020 in England, Wales, and Northern Ireland. Frontiers in Endocrinology, 0, 13, .	1.5	0
391	Association between the number of oocytes and cumulative live birth rate: A systematic review. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2023, 87, 102307.	1.4	9
392	Treatment algorithms for high responders: What we can learn from randomized controlled trials, real-world data and models. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2023, 86, 102301.	1.4	2
393	Factors influencing the number of mature oocytes and cryopreservable blastocysts in hyperresponder patients triggered with a GnRH analog. Journal of Assisted Reproduction and Genetics, 0, , .	1.2	0
394	The Impact of Vitrification in Artificial Reproductive Technology Programmes. European Medical Journal (Chelmsford, England), 0, , 82-89.	3.0	2
395	Ovarian stimulation protocols. , 2023, , 199-204.		0
396	Frozen embryo transfer. , 2023, , 317-324.		0
397	Obstetric and perinatal outcomes following frozen and fresh embryo transfer in patients with endometrial hyperplasia and carcinoma: a retrospective study in a high-volume reproductive center. BMC Pregnancy and Childbirth, 2023, 23, .	0.9	1
398	Ganirelix and the prevention of premature LH surges. F&S Reports, 2023, , .	0.4	0
399	Spontaneous and iatrogenic ovarian hyperstimulation syndrome in the absence of FSHR mutations: a case report of two unexpected cases. BMC Medical Genomics, 2023, 16, .	0.7	0
400	Comparing endometrial preparation methods in frozen embryo transfers â€“ Does a previous live birth make a difference?. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2023, 284, 52-57.	0.5	0
401	Searching for the optimal number of oocytes to reach a live birth after inÂvitro fertilization: a systematic review with meta-analysis. F&S Reviews, 2023, 4, 101-115.	0.7	0
403	The pregnancy results were not affected from the administration day of Depot GnRH agonists in artificial cycle frozen-thawed embryo transfers. Journal of Medicine and Palliative Care:, 2023, 4, 89-93.	0.0	0
404	Role of intramuscular progesterone supplementation on the day of embryo transfer in artificial frozen cycles. Middle East Fertility Society Journal, 2023, 28, .	0.5	0
416	Risiken und Komplikationen der Kinderwunschbehandlung. , 2023, , 405-420.		0
418	Triggering final oocyte maturation. The role of human chorionic gonadotropin, gonadotropin-releasing hormone agonist, and dual trigger. , 2024, , 189-196.		0
419	Fertility preservation. , 2024, , 239-252.		0

#	Article	IF	Citations